Insider · CIK 0001876655
Craig B Granowitz
Files at LXRX (LEXICON PHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Craig B Granowitz files SEC Form 4 as officer at LXRX (LEXICON PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Craig B Granowitz has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +35,790 | - | - | 156,042 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +74,226 | - | - | 230,268 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +202,260 | - | - | 432,528 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -109,098 | $1.47 | $160k | 323,430 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -35,790 | - | - | 0 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -74,226 | - | - | 74,227 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -202,260 | - | - | 404,520 | Mar 3, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +346,610 | $0.00 | $0 | 346,610 | Feb 17, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +519,920 | $0.00 | $0 | 519,920 | Feb 17, 2026 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +27,917 | - | - | 75,543 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +35,790 | - | - | 111,333 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +74,227 | - | - | 185,560 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -65,308 | $0.67 | $44k | 120,252 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -27,917 | - | - | 0 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -35,790 | - | - | 35,790 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -74,227 | - | - | 148,453 | Mar 3, 2025 |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +910,170 | $0.00 | $0 | 910,170 | Feb 18, 2025 |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +606,780 | $0.00 | $0 | 606,780 | Feb 18, 2025 |
Questions about Craig B Granowitz
Answered from the filings on this page, as of the latest one.
Is Craig B Granowitz buying or selling?
Craig B Granowitz has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Craig B Granowitz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Craig B Granowitz has 0.
Where does Craig B Granowitz file Form 4?
Craig B Granowitz has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.) as SVP, Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.